The FDA plans to approve selected high-priority drug application submissions in 1 to 2 months rather than 10 to 12.

Rates of proven drug hypersensitivity reactions are comparable between children with and without inborn errors of immunity (IEI).

Automated data review assists in identifying problematic opioid usage, outperforming manual methods in sensitivity and positive predictive value.

Mortality rates associated with calciphylaxis are lower than previously observed, with rates of 28.88% at 1-year and 29.92% at 2-years.

Research on the preferences of patients with AD, caregivers, and health care providers may be influenced by pharmaceutical company sponsorship.